Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection

Key facts

Sponsor

Universidad Peruana Cayetano Heredia

Principal Investigator

Eduardo Gotuzzo, MD

Instituto de Medicina Tropical Alexander von Humboldt

Intervention

"Raltegravir" and "Zidovudine"(drug)

Enrollment

10 enrolled

Eligibility

18 years · All sexes

Timeline

2017 – 2019

Study locations (1)

• Instituto de Medicina Tropical Alexander von Humboldt, Lima, Peru

Collaborators

Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Tropical spastic paraparesis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT04799288
  Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
  National Institute of Neurological Disorders and Stroke (NINDS)
• RECRUITINGNCT00001778
  Evaluation of Patients With HAM/TSP
  National Institute of Neurological Disorders and Stroke (NINDS)

See all trials for Tropical spastic paraparesis →